Desvenlafaxine
Product Images NDC 68151-5295

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 68151-5295). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 2: Impact Of Desvenlafaxine On Pharmacokinetics (pk) Of Desipramine, Midazolam, Tamoxifen And Aripiprazole (Image 01)

This text contains information about Desvenlafaxine and its interaction with other drugs, such as Desipramine, Midazolam, Tamoxien, and Ariprazole. It also provides recommendations for dose adjustments based on fold change and relative to reference values. No dose adjustment is recommended for Desvenlafaxine ER 400 mg and Desveniafaxine ER 100 mg, while a reduction of up to one-half is recommended for Desvenlataxine ER 100 mg.*

FDA Label Image

Figure 3: Impact Of Intrinsic Factors (renal, Hepatic Impairment And Population Description) (Image 02)

This is a pharmacological document that provides information about the effect of renal and hepatic impairment on the recommended dosage of a drug. The text includes details about dosage adjustment for patients with different levels of renal and hepatic impairment, population description including gender and age, and fold change and 90% CI recommendations. However, the name of the drug is not available.*

FDA Label Image

Figure 1: Impact Of Other Drugs On Desvenlafaxine Pharmacokinetics (pk) (Image 03)

FDA Label Image

Desvenlafaxine Structural Formula (Image 04)

FDA Label Image

Figure 4: Estimated Proportion Of Relapses Vs. Number Of Days Since Randomization (study 5) (Image 07)

FDA Label Image

Figure 5: Estimated Proportion Of Relapses Vs. Number Of Days Since Randomization (study 6) (Image 08)

This appears to be a graph or chart that compares the estimated proportion of patients with relapse over time for two different treatments: Desvenlafaxine Extended-Release Tablets and a placebo. The x-axis displays time to relapse in days, while the y-axis represents the estimated proportion of patients with relapse, measured as a percentage. However, without a visual representation, it is difficult to interpret the results accurately.*

FDA Label Image

Label Image (Lbl681515295)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.